Sara Ansari, R.D. Registered Dietitian, Nutrition Consultant, and Prevent Health Coach joins Lisa and talks anout the biggest obstacles to healthy eating that people face during the holiday season, best tips and strategies to staying healthy while at a holiday party, things people can do to mentally prepare for the holidays, emotional and stress eating and more!
SAN DIEGO, Dec. 19, 2013 – ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for treatment of diabetes, announced today that Mark G. Foletta has been appointed to its Board of Directors. Mr. Foletta is a seasoned financial executive with over 30 yearsof corporate experience. He was most recently senior vice president and Chief Financial Officer at Amylin Pharmaceuticals, Inc. He joined Amylin in 2000 and served through its acquisition by Bristol-Myers Squibb forapproximately $7 billion in August 2012. During his time at Amylin the company grew from 75 to over 1,300 employees and he was instrumental leading numerous strategic transactions with global pharmaceutical companies, as well as public and private financing transactions. As chair of Amylin’s Operating Committee, he had responsibility for business planning, forecasting and assessing performance. He also participated in the commercial launch of three novel pharmaceutical products that generated annual revenues reaching over $700M. Prior to Amylin, Mr. Foletta worked 14 years at Intermark, Inc./Triton Group Ltd. where he served as senior vice president,Chief Financial Officer and Corporate Secretary.
MALVERN, Pa., Dec. 17, 2013 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced the closing of its initial public offering of 7,150,000 shares of its common stock at a public offering price of$7.00 per share, before the underwriting discount and offering costs. As a result, aggregate net proceeds to TetraLogic, after the underwriting discount and offering costs, were approximately $43,100,000.
GUEST MENTOR Andréa Mallard, Chief Brand Officer at Omada Health: As an entrepreneur, the problem with negative feedback of any kind is that it’s instantly personal: they might as well have called your newborn ugly.
OncoMed and Celgene Announce Strategic Collaboration Advancing Multiple Anti-Cancer Stem Cell Therapeutics to Offer Potential Benefits to Cancer Patients
REDWOOD CITY, Calif., Dec. 3, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED) and Celgene Corporation (Nasdaq:CELG) today announced an agreement to jointly develop and commercialize up to six anti-cancer stem cell (CSC) product candidates from OncoMed's biologics pipeline, including demcizumab (OMP-21M18, Anti-DLL4).
...One Bay Area–based company, Omada Health, is making strides in addressing the prediabetes epidemic. The Omada Health program, Prevent, is an online version of a 2002 government-financed project sponsored by the National Institutes of Health called the Diabetes Prevention Program, which found that behavioral weight-loss programs can be more effective at combating diabetes than medication.